however, some discontinuations were actually due to "perceived excessive weight loss," highlighting the potency of the drug
Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease
Whether this pathway fits your situation depends on individual factors, including health history, eligibility, preferences for care delivery, and comfort with either FDA-approved or compounded medication options
These changes correlate with observed effects in animal models
Frontiers in Microbiology 8
The side effects profile of GLP-1 RAs overlaps with IBS symptoms, but with proactive management these side effects are usually temporary and tolerable